KDM6A and prostate carcinoma: UTX is one of a few cancer suppressors that escape X inactivation, leading to a predominant occurrence rate in the male population.270 According to the analyses of 4,742 human tumor specimens.302 UTX is highly mutated across various cancers, including acute lymphoblastic leukemia,303 chronic myelomonocytic leukemia,304 bladder cancer,305 medulloblastoma,306 prostate cancer,307 and renal carcinoma.308 The proliferation of cancer cells was reduced when inactivating UTX mutations were resumed with the addition of wild-type UTX.